Fundz

Jaguar Health

SAN FRANCISCO, California, United States · Healthcare, Health Care

Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harves

Key facts

Headquarters
SAN FRANCISCO, California, United States
Employees
39
Industries
Healthcare, Health Care
Status
Public (JAGX)
Website
jaguar.health
LinkedIn
Company page

Recent activity at Jaguar Health

  • : SEC 8-K (7.01): On November 6, 2026, Jaguar Health, Inc. issued a press release announcing the results of a Special Meeting. This meeting likely had significant outcomes that may impact shareholders and the business, though specific details regarding the content of the results are outlined in Exhibit 99.1, which is attached to the filing. The press release itself is dated the same day, signaling timely communication with investors. As the disclosure is aimed at informing stakeholders, it falls under Regulation FD, which ensures that all investors have equal access to material information.
  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On September 30, 2026, Jaguar Health, Inc. entered into an amendment to the Uptown 2020 Royalty Interest with Uptown Capital, LLC, which involves a principal amount of $12 million. The amendment modifies the initiation of monthly payments to January 1, 2027, extending the timeline for financial obligations. The scheduled monthly payment is established at a minimum of $750,000 or the actual royalty amount owed, whichever is greater. This adjustment may impact the company's cash flow and financial planning for the upcoming fiscal period.
  • : SEC 8-K (1.01): On September 25, 2026, Jaguar Health, Inc. entered into material definitive agreements to exchange an aggregate of 481,584 shares of its common stock for a $3,400,000 reduction in the outstanding balance of a previously issued secured promissory note, originally dated January 19, 2021, with Streeterville Capital, LLC. This transaction effectively reduces the principal amount owed on the note from $6,220,812.50, providing the company with improved financial flexibility. The agreements contributed to the restructuring of the company's obligations and emphasized the company's ongoing relationship with Streeterville, which could have further strategic implications for financing and operational capabilities.
  • : SEC 8-K (1.01): On September 23, 2026, Jaguar Health, Inc. entered into privately negotiated exchange agreements with Streeterville Capital, LLC to reduce the outstanding principal balance of a previously issued promissory note. In this transaction, the Company issued 182,091 shares of its common stock to Streeterville in exchange for a reduction of $1,678,320 in the 2021 Note's outstanding balance. The initial promissory note, part of a Note Purchase Agreement from January 19, 2021, had an original principal amount of $6,220,812.50. This strategic stock exchange may indicate a financial restructuring effort to improve the Company's balance sheet and alleviate debt obligations.
  • : SEC 8-K (1.01): On September 23, 2026, Jaguar Health, Inc. entered into a material definitive agreement with Streeterville Capital, LLC for the exchange of a portion of a secured promissory note originally issued on November 12, 2025. Under the terms of the 2025 Note Exchange Agreements, Jaguar Health issued 547,898 shares of its common stock worth approximately $5,049,909.26 to Streeterville in exchange for a reduction in the outstanding balance of the $10,810,000 promissory note. This transaction aims to adjust the financial obligations under the note while providing equity to Streeterville, which could have significant implications for the company's capital structure and cash flows moving forward.
  • : SEC 8-K (8.01):
  • : SEC 8-K (7.01): On September 15, 2026, Jaguar Health, Inc. issued a press release announcing the effectuation of a Reverse Stock Split. This significant corporate action may impact the company's stock valuation and shareholder equity. The announcement details were provided in Exhibit 99.1, indicating that this disclosure is intended for clarity under Regulation FD and is not considered 'filed' under the Exchange Act. This action reflects the company's strategy to better position its stock in the market. The Reverse Stock Split occurred on the same date as the announcement.
  • : SEC 8-K (1.01): On September 11, 2026, Jaguar Health, Inc. entered into a privately negotiated exchange agreement (the 'LAS Exchange Agreement') with Lincoln Alternative Strategies LLC, exchanging 557,377 shares of common stock for a total outstanding balance of $175,016.36 of a 6% convertible promissory note, which was subsequently surrendered and cancelled. Additionally, on the same date, a separate exchange agreement with Streeterville Capital, LLC involved issuing 219,435 shares of common stock in exchange for 2.8 outstanding shares of Series Q Preferred Stock, alongside a prior agreement that had already issued 53,191 shares for 6 shares of preferred stock. These transactions collectively resulted in significant changes to the company's capital structure, with the issuance exceeding 5% of its total shares, impacting shareholder dilution and liquidity.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Jaguar Health funding history

DateRoundAmount
Jun 2026Venture$2.0M
Nov 2025Venture$10.8M
Sep 2025Seed$1.0M
Sep 2025Seed$2.4M
May 2025Seed$1.5M

Leadership

  • Lisa Conte, Executive Officer, Director
  • James Bochnowski, Director
  • John III, Director
  • Jonathan Siegel, Director
  • Anula Jayasuriya, Director
  • Greg Divis, Director

Verified email and direct lines for Jaguar Health’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Jaguar Health files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Jaguar Health in the news

Companies similar to Jaguar Health

About Jaguar Health: questions and answers

What does Jaguar Health do?

Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harves

Where is Jaguar Health headquartered?

Jaguar Health is headquartered in SAN FRANCISCO, California, United States.

How many employees does Jaguar Health have?

Jaguar Health has about 39 employees.

Has Jaguar Health raised funding?

Yes. Fundz has recorded 5 funding events for Jaguar Health. The most recent, $2.0M, was in Jun 2026.

What is the latest news on Jaguar Health?

On May 4, 2026, SEC 8-K (7.01): On November 6, 2026, Jaguar Health, Inc. issued a press release announcing the results of a Special Meeting. This meeting likely had significant outcomes that may impact shareholders and the business, though specific details regarding the content of the results are outlined in Exhibi

Is Jaguar Health a public company?

Yes. Jaguar Health is publicly traded under the ticker JAGX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Jaguar Health across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.